Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine in XMEN Patients
NCT07555405Phase 4Not yet recruiting
- Sponsor
- Children's Hospital of Fudan University
- Start
- Apr 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of decitabine in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia (XMEN), sponsored by Children's Hospital of Fudan University. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
decitabine
03
Conditions
X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia (XMEN)
Beyond the preview
Go deeper on NCT07555405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07555405.